Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2021-0602
Abstract: Bruton's tyrosine kinase inhibitors have changed the treatment landscape for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and lymphoplasmacytic lymphoma dramatically. In 2019, acalabrutinib was approved by the US FDA for the treatment of treatment-naive and… read more here.
Keywords: lymphocytic leukemia; acalabrutinib use; chronic lymphocytic; acalabrutinib ... See more keywords